GH

Guardant Health, Inc.

October 6, 2026 · intraday

Rarity

1.62

Peak move

−8.81%

Float cap

$23.6B

Guardant Health is a precision oncology company that provides blood and tissue tests, real-world data, and AI analytics for cancer care. Its products are used for early cancer screening, recurrence monitoring, and treatment selection, and are sold to oncologists, health systems, biopharmaceutical companies, and screening providers.

• clinical_readoutOct 5 · 06:27 ET

  Cancer Research Communications published the COSMOS-MEL01 study of Guardant Health's tissue-free Guardant Reveal blood test in 48 resected stage II-III melanoma patients, showing 81% sensitivity for distant recurrence, 100% post-treatment specificity, and a median 70.5-day lead over clinical detection.

  Webinvestors.guardanthealth.comWebmarketscreener.comWebwwww.stockwatch.com
• insider_saleOct 2

  Guardant Health disclosed insider transactions on October 2, 2026, including Chief Technology Officer Darya Chudova selling 4,320 shares at $174.75 on October 1, 2026, leaving her 74,348 shares.

  Webstockpage.10jqka.com.cnWebbasic.10jqka.com.cn
• analyst_ratingOct 1

  Guggenheim Investments raised its price target on Guardant Health to $200 and maintained a Buy rating.

  Webemweb.eastmoney.com